Login / Signup

MLL3 is a de novo cause of endocrine therapy resistance.

Kimberly M StaufferDavid L ElionRebecca S CookThomas P Stricker
Published in: Cancer medicine (2021)
Our data show that a decrease in functional MLL3 leads to endocrine therapy resistance. This highlights the importance of genotyping patient tumor samples for MLL3 mutation upon initial resection, prior to deciding upon treatment plans.
Keyphrases
  • acute myeloid leukemia
  • genome wide
  • case report
  • stem cells
  • high throughput
  • gene expression
  • big data
  • machine learning
  • dna methylation
  • replacement therapy
  • mesenchymal stem cells
  • artificial intelligence